The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Lenalidomide + rituximab in MCL: 7-year follow-up analysis
Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, discusses the 7-year follow-up of a multicenter, Phase II study (NCT01472562) aiming to evaluate the efficacy and safety of combined lenalidomide and rituximab treatment in mantle cell lymphoma (MCL) patients. The 7-year progression-free survival rate was estimated at 60.3% with 7-year overall survival rates at 73.2%. Treatment-emergent adverse events were managed in outpatient settings and only two cases of secondary primary malignancies were reported. These findings show that combined initial treatment with lenalidomide and rituximab can achieve high rates of complete responses with durable remissions in MCL, with many patients maintaining remissions now extending beyond 7 years. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
